To quantify the probability that monthly intravenous (IV) and subcutaneous (SC) natalizumab (NTZ) had similar efficacy in relapsing-remitting multiple sclerosis (RRMS), non-inferiority of efficacy of NTZ-SC versus NTZ-IV on combined MRI unique active lesions number (CUAL) was explored re-analysing the REFINE data set. Non-inferiority margins were selected equal to 25%/33%/50% fractions of the effect size of NTZ-IV versus placebo observed in the AFFIRM study. Ninety-nine RRMS were included. NTZ-SC resulted not inferior to NTZ-IV on CUAL for all margins at 2.5% significance level, and, in worst-case scenario, its effect over NTZ-IV did not exceed 3.5% (or 2.8%) of the effect of NTZ-IV versus placebo.
PlavinaTFoxEJLucasN, et al. A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis. J Clin Pharmacol2016; 56(10): 1254–1262.
3.
TrojanoMRamió-TorrentàLGrimaldiLM, et al. A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis. Mult Scler2021; 27(14): 2240–2253.
4.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
5.
ZamboniPTesioLGalimbertiS, et al. Efficacy and safety of extracranial vein angioplasty in multiple sclerosis: A randomized clinical trial. JAMA Neurol2018; 75: 35–43.
FilippiMGrimaldiLConteA, et al. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: Investigation on efficiency and savings-the EASIER study. J Neurol2023; 20: 44.
8.
TooropAAvan KempenZLESteenhuisM, et al. Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry2023; 94(6): 482–486.
